MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

Table 1 Patient characteristics in the entire cohort and according to central HER2 status

	N	%	N	%	N	%	p value
Menopausal status
Pre	71	31	28	31.1	43	30.9	0.98
Post	158	69	62	68.9	96	69.1
Performance status (N = 225)
0	164	72.9	63	70.8	101	74.3	0.38
1	47	20.9	18	20.2	29	21.3
2–3	14	6.2	8	9	6	4.4
History (N patients with available data)
Adjuvant CT (N = 228)	133	58.3	55	61.8	78	56.1	0.40
Adjuvant CT anthracycline (N = 227)	90	39.6	29	33	61	43.9	0.10
Adjuvant CT taxanes (N = 227)	55	24.2	17	19.3	38	27.3	0.17
Adjuvant RT (N = 224)	87	38.8	35	39.8	52	38.2	0.82
Adjuvant HT (N = 227)	108	47.6	45	51.1	63	46.3	0.48
Line of treatment
1st line	192	83.8	68	75.6	124	89.2
2nd line	31	13.5	18	20.0	13	9.4
3rd line	2	0.9	2	2.2	0	0.0
4th line	2	0.9	1	1.1	1	0.7
5th line	1	0.4	0	0.0	1	0.7
6th line	0	0.0	0	0.0	0	0.0
7th line	1	0.4	1	1.1	0	0.0
Histological grade (N = 214)
I–II	94	43.9	40	47.6	54	41.5	0.38
III	120	56.1	44	52.4	76	58.5
Metastatic sites
Locoregional	73	31.9	28	31.1	45	32.4	0.84
Distant	203	88.6	83	92.2	120	86.3	0.17
Bones	98	42.8	41	45.6	57	41.3	0.53
Visceral	155	67.7	60	66.7	95	68.3	0.79
Number of metastatic sites
<3	166	72.4	65	72.2	101	72.7	0.87
≥3	63	27.6	25	27.8	38	27.3

ISSN: 1479-5876